Cytokinetics, Incorporated
CYTK
$43.27
-$0.61-1.39%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 145.34% | -58.81% | -68.51% | -66.05% | -0.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 145.34% | -58.81% | -68.51% | -96.17% | -92.04% |
| Cost of Revenue | 2.81% | 3.31% | 9.42% | 21.13% | 37.09% |
| Gross Profit | 0.51% | -4.86% | -12.10% | -86.40% | -120.61% |
| SG&A Expenses | 24.02% | 7.43% | -5.76% | -12.91% | -2.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.12% | 4.81% | 3.51% | 7.01% | 20.28% |
| Operating Income | -8.07% | -5.81% | -5.00% | -34.29% | -53.05% |
| Income Before Tax | -12.03% | -9.43% | -1.05% | -23.17% | -35.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.03% | -9.43% | -1.05% | -23.17% | -35.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.03% | -9.43% | -1.05% | -23.17% | -35.30% |
| EBIT | -8.07% | -5.81% | -5.00% | -34.29% | -53.05% |
| EBITDA | -8.76% | -4.61% | -3.78% | -33.22% | -52.11% |
| EPS Basic | 3.20% | 2.39% | 5.62% | -17.98% | -28.21% |
| Normalized Basic EPS | 3.20% | 2.40% | 1.52% | -24.43% | -36.87% |
| EPS Diluted | 3.20% | 2.39% | 5.62% | -17.98% | -28.21% |
| Normalized Diluted EPS | 3.20% | 2.40% | 1.52% | -24.43% | -36.87% |
| Average Basic Shares Outstanding | 15.77% | 12.12% | 7.10% | 6.36% | 7.49% |
| Average Diluted Shares Outstanding | 15.77% | 12.12% | 7.10% | 6.36% | 7.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
